GlassScriptPhysician profile
Peter M Kally
NPI 1730534801
$25,889.70
in general payments reported to CMS, 2019-2025
16 companies · $6,906 in 2025
The $6,906 reported for 2025 was more than what 87% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $266 · 2021: $264 · 2022: $1,640 · 2023: $2,557 · 2024: $14K · 2025: $6,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $5,100 · Food and Beverage: $3,797 · Travel and Lodging: $2,913 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,900.00 |
| Consulting Fee | $5,100.00 |
| Food and Beverage | $3,796.96 |
| Travel and Lodging | $2,912.95 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20,748.82 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $2,654.98 | 2022-2023 | |
| Horizon Therapeutics Plc | $752.98 | 2023 | Tepezza |
| Abbvie INC. | $428.08 | 2023-2024 | |
| Merz Pharmaceuticals, LLC | $369.49 | 2023-2025 | Xeomin |
| Alcon Vision LLC | $143.56 | 2020 | |
| Sight Sciences, INC. | $137.61 | 2022 | |
| Bausch & Lomb Americas INC. | $122.56 | 2022 | |
| Biogen, INC. | $122.43 | 2020 | |
| Aerie Pharmaceuticals, INC. | $119.32 | 2021 | |
| Allergan, INC. | $111.51 | 2021 | |
| Axogen | $62.02 | 2023 | Avance Nerve Graft |
| Depuy Synthes Sales INC. | $42.62 | 2023 | Trumatch |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.45 | 2021 | |
| Sun Pharmaceutical Industries INC. | $22.21 | 2023 | Cequa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $18.06 | 2025 | Artiss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.